Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Stock Information for Cardiff Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cardiff Oncology Inc.

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.